Oncology CRO | Charles River Discovery Research Services

Intratibial Tumor Model 

Charles River has developed intratibial models simulating the disease process to address the challenge of modeling bone lysis and infrequent spontaneous bone metastases. Various cell lines and positive controls as well as combination therapies have been validated in our hands. This model allows for the evaluation of a novel compound's effect on bone lysis or blastic activity.

The study design can incorporate client-driven service additions, including:

  • Treatment efficiency
  • Histopathology
  • Histomorphometry
  • Immunohistochemistry

Distant Metastases in Intratibial Tumor Model Quantified by Histopathology
  Distant Metastases Quantified by Histopathology


The Charles River model provides for:

  • Intratibial injection of tumor cells to induce bone resorption
  • Radiographic quantification of test agents' effects

Data

Chart showing bone density of treated and untreated 13762 rat mammary carcinoma in Fischer 344 rats


13762 Rat Mammary Carcinoma in Fischer 344 Rats

 

For more information about our intratibial tumor model, please contact us at 1.877.CRIVER.1 or askcharlesriver@crl.com.

Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
Jun 13 - Neurological Biomarkers in Efficac...
Jun 06 - GLP-Compliant ELISpot and FluoroSp...
Jun 24-Jun 26 - London, UK - Skin Forum 2013
Jun 21-Jun 25 - Chicago, IL - American Diabetes Association’s 73rd Scientific Sessions
Sep 09-Sep 11 - Carlsbad, CA - 19th Annual Biotechnology-Derived Therapeutics Perspecti...
Jun 18-Jun 18 - Basel, Switzerland - Seminar: Behavioral Biology in Mice and Rats

Charles River Laboratories, Inc.